
Claims

1. Use of Compound (I):



Compound (I)

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a subject having heart failure, wherein Compound (I) or a pharmaceutically acceptable salt thereof is to be administered from 5 mg to 360 mg per day.

2. The use of claim 1, wherein Compound (I) or a pharmaceutically acceptable salt thereof is Compound (I).

3. The use of claim 1 or claim 2, wherein the amount of Compound (I) or a pharmaceutically acceptable salt thereof administered to the subject is from 20 mg to 360 mg per day.

4. The use of any one of the preceding claims, wherein the amount of Compound (I) or a pharmaceutically acceptable salt thereof administered to the subject is from 20 mg to 100 mg per day, optionally 20 mg to 80 mg per day.

5. The use of claim 1 or claim 2, wherein the amount of Compound (I) or a pharmaceutically acceptable salt thereof administered to the subject is about 20 mg per day, about 80 mg per day, or about 360 mg per day.

6. The use of any one of claims 1 to 5, wherein Compound (I) or a pharmaceutically acceptable salt thereof is to be administered to the subject orally.

7. The use of any one of claims 1 to 6, wherein Compound (I) or a pharmaceutically acceptable salt thereof is to be administered to the subject once daily.

8. The use of any one of claims 1 to 6, wherein Compound (I) or a pharmaceutically acceptable salt thereof is to be administered to the subject twice daily.

9. The use of claim 1, wherein a pharmaceutical composition comprising a pharmaceutically acceptable excipient and from 5 mg to 360 mg of Compound (I) or a pharmaceutically acceptable salt thereof is to be administered to the subject once daily.

10. The use of claim 9, wherein the pharmaceutical composition comprises from 20 mg to 100 mg of Compound (I) or a pharmaceutically acceptable salt thereof, optionally from 20 mg to 80 mg of Compound (I) or a pharmaceutically acceptable salt thereof.

11. The use of claim 1, wherein a pharmaceutical composition comprising a pharmaceutically acceptable excipient and from 5 mg to 180 mg of Compound (I) or a pharmaceutically acceptable salt thereof is to be administered to the subject twice daily.

12. The use of claim 11, wherein the pharmaceutical composition comprises from 10 mg to 50 mg of Compound (I) or a pharmaceutically acceptable salt thereof, optionally from 10 mg to 40 mg of Compound (I) or a pharmaceutically acceptable salt thereof.

13. The use of any one of claims 9 to 12, wherein the pharmaceutical composition is in the form of one or more tablets and is to be administered to the subject orally.

14. The use of any one of claims 9 to 12, wherein the pharmaceutical composition is in the form of a single tablet and is to be administered to the subject orally.

15. The use of claim 1, wherein a tablet comprising from 20 mg to 180 mg of Compound (I) is to be administered orally to the subject once daily.

16. The use of claim 1, wherein a tablet comprising from 10 mg to 100 mg of Compound (I) is to be administered orally to the subject twice daily.

17. The use of any one of the preceding claims, wherein Compound (I) or a pharmaceutically acceptable salt thereof is to be administered to the subject for one or more weeks.

18. The use of any one of the preceding claims, wherein Compound (I) or a pharmaceutically acceptable salt thereof is to be administered to the subject chronically.

19. The use of any one of the preceding claims, wherein administration to the subject of Compound (I) or a pharmaceutically acceptable salt thereof is capable of:

- causing no significant change in blood pressure of the subject relative to baseline blood pressure of the subject; and/or
- causing no significant change in resting heart rate of the subject relative to baseline resting heart rate of the subject; and/or
- resulting in a decrease in end systolic volume (ESV) of the subject as compared to baseline levels, such as results in a decrease in ESV of at least 10%, as compared to baseline levels; and/or
- resulting in an increase in ejection fraction (EF) of the subject as compared to baseline levels, such as results in an increase in EF of at least 5%, as compared to baseline levels; and/or
- resulting in an increase in stroke volume (SV) of the subject as compared to baseline levels; and/or
- resulting in a decrease in systemic vascular resistance (SVR) of the subject as compared to baseline levels, such as results in a decrease in SVR in the subject of at least 5%, as compared to baseline levels; and/or
- resulting in a decrease in serum creatinine of the subject as compared to baseline levels; and/or
- resulting in an increase in renin of the subject as compared to baseline levels, such as results in an increase in renin of at least 10%, as compared to baseline levels; and/or
- resulting in an increase in estimated glomerular filtration rate (eGFR) of the subject as compared to baseline levels, such as results in an increase in eGFR of at least 1%, as compared to baseline levels; and/or
- resulting in an increase in 6-minute walking distance (6MWD) of the subject as compared to baseline levels; and/or
- resulting in an increase in Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ TSS) of the subject as compared to baseline levels; and/or

- resulting in maintenance or an improvement in New York Heart Association Functional Class (NYHA FC) of the subject as compared to baseline levels; and/or
- resulting in a decrease in N-terminal prohormone of brain natriuretic peptide (NT-proBNP) of the subject as compared to baseline levels.

20. The use of claim 19, wherein the change in ESV, EF, SV, SVR, serum creatinine, renin, eGFR, 6MWD, KCCQ TSS, NYHA FC and/or NT-proBNP is as measured after 1-24 weeks of treatment, optionally after 24 weeks of treatment.

21. The use of any one of the preceding claims, wherein the heart failure is heart failure with preserved ejection fraction (HFpEF), heart failure with ejection fraction ≥ 41% (HF with EF ≥ 41%), heart failure with mid-range ejection fraction (HFmrEF), heart failure with reduced ejection fraction (HFrEF) or heart failure with ejection fraction ≤ 35% (HF with EF ≤ 35%).

22. A pharmaceutical composition comprising from 5 mg to 360 mg of Compound (I) or a pharmaceutically acceptable salt thereof.

23. The pharmaceutical composition of claim 22, comprising from 20 mg to 180 mg of Compound (I) or a pharmaceutically acceptable salt thereof.

24. The pharmaceutical composition of claim 22 or 23, wherein the pharmaceutical composition is in the form of a tablet suitable for oral administration.

25. Use of the pharmaceutical composition of any one of claims 22 to 24 in the manufacture of a medicament for treating a subject having heart failure.